This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

This study has been completed.
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Sandoz Identifier:
First received: January 10, 2011
Last updated: December 16, 2016
Last verified: December 2016
The purpose of this study is to determine the PK/PD, efficacy and safety of GP2013 in patients with severe rheumatoid arthritis.

Condition Intervention Phase
Rheumatoid Arthritis Biological: GP2013 Biological: rituximab Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Controlled Study to Evaluate PK, PD, Safety and Efficacy of GP2013 and Rituximab in Patients With Rheumatoid Arthritis Refractory or Intolerant to Standard DMARDs and up to Three Anti-TNF Therapies.

Resource links provided by NLM:

Further study details as provided by Sandoz:

Primary Outcome Measures:
  • Compare pharmacokinetics (PK) of GP2013 and rituximab following IV infusion in patients with RA [ Time Frame: 24 weeks ]

Secondary Outcome Measures:
  • Additional pharmacokinetic (PK) parameters, pharmacodynamic (PD) and efficacy of GP2013 and rituximab in subjects with RA [ Time Frame: 1.5 years ]
  • Safety and tolerability of GP2013 and rituximab in patients with RA [ Time Frame: 1.5 years ]

Enrollment: 139
Study Start Date: January 2011
Study Completion Date: November 2016
Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GP2013 Biological: GP2013
1000 mg
Active Comparator: rituximab Biological: rituximab
1000 mg


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Rheumatoid arthritis as defined by the 1987 ACR classification
  • Severe active seropositive disease
  • Inadequate response or intolerance to other DMARDs and anti-TNFs
  • Treatment with Methotrexate

Exclusion Criteria:

  • Patients with systemic manifestations of rheumatoid arthritis
  • Female patients nursing
  • Women of childbearing potential unless using birth control
  • Active infection
  • Known immunodeficiency syndrome
  • Positive Hepatitis B surface antigen or antibodies to Hepatitis C
  • History of cancer

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01274182

  Hide Study Locations
United States, California
Miller Clinical Research
Los Angeles, California, United States, 90057
United States, Kentucky
Bluegrass Community Research, Inc.
Lexington, Kentucky, United States, 40504
United States, Maryland
Klein & Associates
Cumberland, Maryland, United States, 21502
Klein & Associates
Hagerstown, Maryland, United States, 21740
United States, Massachusetts
Clinical Pharmacology Study Group
Worcester, Massachusetts, United States, 01605
United States, Nebraska
Physician Research Collaboration, LLC
Lincoln, Nebraska, United States, 68516
United States, Nevada
Innovative Health Research
Las Vegas, Nevada, United States, 89128
United States, North Carolina
DJL Clinical Research PLLC
Charlotte, North Carolina, United States, 28210
United States, Oklahoma
Health Research of Oklahoma
Oklahoma City, Oklahoma, United States, 73103
United States, Pennsylvania
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States, 16635
Clinical Research Center of Reading LLC
Wyomissing, Pennsylvania, United States, 19610
United States, South Carolina
Low Country Rheumatology, PA
Charleston, South Carolina, United States, 29406
United States, South Dakota
Regional Health Clinical Research
Rapid City, South Dakota, United States
United States, Tennessee
West Tennessee Research Institute
Jackson, Tennessee, United States, 38305
United States, Texas
Arthritis & Osteoporosis Center of South Texas
San Antonio, Texas, United States, 78232
United States, Washington
The Seattle Arthritis Center
Seattle, Washington, United States, 98133
Investigative Site
Buenos Aires#1, Argentina
Investigative Site
Buenos Aires#2, Argentina
Investigative Site
Innsbruck, Austria
Investigative Site
Vienna#1, Austria
Investigative site
Kortrijk, Belgium
Investigative site
Merksem, Belgium
Investigative Site
Curitiba, Brazil
Investigative Site
Goiânia, Brazil
Investigative Site
Sao Paulo#1, Brazil
Investigative site
Sao Paulo#2, Brazil
Investigative Site
Amiens Cedex, France
Investigative site
Cahors, France
Investigative Site
Corbeil Essonnes, France
Investigative site
La Gaillarde, France
Investigative Site
Orleans, France
Investigative Site
Frankfurt, Germany
Investigative Site
Freiburg, Germany
Investigative Site
Göttingen, Germany
Investigative Site
Hildesheim, Germany
Investigative Site
Jena, Germany
Investigative Site
München, Germany
Investigative Site
Nürnberg, Germany
Investigative Site
Ratingen, Germany
Investigative Site
Regensburg, Germany
Investigative Site
Würzburg, Germany
Investigative site
Ajmer, India
Investigative Site
Bangalore, India
Investigative Site
Hyderabad, India
Investigative Site
Jaipur, India
Investigative Site
New Delhi, India
Investigative Site
Secunderabad, India
Investigative Site
Milano, Italy
Investigative site
Bucharest#1, Romania
Investigative site
Bucharest#2, Romania
Investigative site
Cluj, Romania
Investigative Site
Madrid, Spain
Investigative site
Majadanonda, Spain
Investigative Site
Mérida, Spain
Investigative site
Santiago de Compostela, Spain
Investigative Site
Sevilla, Spain
Investigative Site
Istanbul, Turkey
Investigative Site
Izmir, Turkey
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Sandoz Biopharmaceuticals Sandoz
  More Information

Responsible Party: Sandoz Identifier: NCT01274182     History of Changes
Other Study ID Numbers: GP13-201
2010-021184-32 ( EudraCT Number )
GPN013A2301 ( Other Identifier: Novartis )
Study First Received: January 10, 2011
Last Updated: December 16, 2016

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents processed this record on August 18, 2017